Dr. Reddy – Artifex.News https://artifex.news Stay Connected. Stay Informed. Mon, 02 Nov 2026 16:15:00 +0000 en-US hourly 1 https://wordpress.org/?v=7.1.4 https://artifex.news/wp-content/uploads/2026/05/cropped-cropped-app-logo-32x32.png Dr. Reddy – Artifex.News https://artifex.news 32 32 Dr. Reddy’s secures U.S. FDA tentative nod for HIV drug lenacapavir https://artifex.news/article71657724-ece/ Mon, 02 Nov 2026 16:15:00 +0000 https://artifex.news/article71657724-ece/ Read More “Dr. Reddy’s secures U.S. FDA tentative nod for HIV drug lenacapavir” »

]]>

Generic drugmaker Dr. Reddy’s Laboratories has received U.S. Food and Drug Administration (U.S. FDA) tentative approval for twice-yearly injectable HIV prevention drug lenacapavir.

The approval was granted under the U.S. FDA’s President’s Emergency Plan for AIDS Relief (PEPFAR) programme. It is an important milestone and reflects the company’s capabilities in developing and manufacturing complex medicines, Dr. Reddy’s said on Monday.

First supplies are expected to reach people by December with broader rollout across eligible countries expected in 2027, it said, announcing the tentative approval for its long-acting injectable lenacapavir for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 77 pounds (35 kg).

The approval builds on the voluntary licence granted by Gilead Sciences to Dr. Reddy’s in October 2024, followed by an agreement with Unitaid, the Wits Reproductive Health and HIV Institute (Wits RHI) and the Clinton Health Access Initiative (CHAI) in September 2025. The agreement was to support product development, accelerate regulatory pathway and enable access to injectable lenacapavir at $40 per person per year across 120 countries in Gilead’s voluntary licence.

“Developing and manufacturing a complex long-acting injectable like lenacapavir at an affordable price required strong scientific capabilities and manufacturing expertise to address an urgent access need. The U.S. FDA approval validates that work…” CEO-API and Services Deepak Sapra said.

The U.S. FDA approval provides an important regulatory basis for the remaining steps towards wider availability, including WHO prequalification and national regulatory approvals, the company said.

CEO of CHAI Neil Buddy Shah said “getting a generic approved just 16 months after the originator shows what’s possible when we prioritise access from the start.”

“Generic lenacapavir has the potential to transform HIV prevention… but an affordable drug alone is not enough. Countries need health systems that are ready to deliver new prevention options, providers who are confident in offering them and communities that are engaged as partners in their introduction and scale-up,” said Saiqa Mullick, Director of Implementation Science at Wits RHI, University of the Witwatersrand.



Source link

]]>
U.S. FDA’s VAI tag for Dr. Reddy’s unit in Srikakulam, inspection closed https://artifex.news/article71637226-ece/ Wed, 28 Oct 2026 16:50:00 +0000 https://artifex.news/article71637226-ece/ Read More “U.S. FDA’s VAI tag for Dr. Reddy’s unit in Srikakulam, inspection closed” »

]]>

The U.S. Food and Drug Administration (U.S. FDA) has classified Dr. Reddy’s Laboratories facility in Srikakulam, Andhra Pradesh, post an inspection, as Voluntary Action Indicated (VAI).

The regulator had issued a Form 483 with three observations following the PreApproval Inspection (PAI) and Good Manufacturing Practices (GMP) inspection of the FTO-SEZ Process Unit-02 in Srikakulam between July 20 and July 29.

“We wish to inform the U.S. FDA has classified the inspection outcome as ‘voluntary action indicated (VAI)’ and concluded that the inspection is officially closed,” Dr. Reddy’s said in a filing on Wednesday.

One of three classifications the U.S. FDA issues, post inspection of pharma facilities, VAI means while objectionable conditions or practices were found, the regulator is not prepared to take or recommend any administrative or regulatory action.

Under OAI, another classification, the U.S. FDA recommends regulatory and/or administrative actions. The third classification is No Action Indicated (NAI) and conveys that no objectionable conditions or practices were found during the inspection.



Source link

]]>
Dr. Reddy’s facility in Andhra Pradesh gets 2 U.S. FDA observations https://artifex.news/article71560061-ece/ Thu, 08 Oct 2026 13:50:00 +0000 https://artifex.news/article71560061-ece/ Read More “Dr. Reddy’s facility in Andhra Pradesh gets 2 U.S. FDA observations” »

]]>

A view of Dr. Reddy’s Lab facility near Hyderabad
| Photo Credit: The Hindu

The U.S. Food and Drug Administration (U.S. FDA) has issued two observations to a manufacturing facility of Dr. Reddy’s Laboratories in Andhra Pradesh.

A Form 483 with the two observations was issued by the U.S. FDA on completion of a pre-approval inspection (PAI) at the company’s FTO-11 manufacturing facility in Pydibhimavaram, Andhra Pradesh. The inspection was conducted from October 5-7. The company will address the observations within the stipulated timeline, Dr. Reddy’s said in a filing on Thursday.

The drugmaker’s shares closed 1.86% lower at ₹1,180 on the BSE.



Source link

]]>
U.S. IRS imposes $32,350 penalty on Dr. Reddy’s arm https://artifex.news/article71547934-ece/ Mon, 05 Oct 2026 14:52:00 +0000 https://artifex.news/article71547934-ece/ Read More “U.S. IRS imposes $32,350 penalty on Dr. Reddy’s arm” »

]]>

A step-down wholly owned U.S. subsidiary of pharma major Dr. Reddy’s Laboratories has been levied a $32,350.20 penalty by the U.S. Internal Revenue Service (IRS).

The penalty on Dr. Reddy’s Laboratories Inc., the subsidiary, is due to misclassification of fiscal year reference at the time of tax payment, the Hyderabad-based parent company said citing the order from the Department of Treasury, Internal Revenue Service, Cincinnati. The company received the final transcript dated September 25, 2026, from the Department, on October 2, 2026 classifying an amount $32,350.20 as a penalty levied by IRS.

Based on its evaluation, of the order, there is no material impact on financials, operations or other activities of the company, Dr. Reddy’s said in a filing on Saturday.



Source link

]]>
Dr. Reddy’s, Takeda Pharma ink pact to distribute India’s first dengue vaccine QDENGA https://artifex.news/article71479880-ece/ Fri, 18 Sep 2026 09:22:00 +0000 https://artifex.news/article71479880-ece/ Read More “Dr. Reddy’s, Takeda Pharma ink pact to distribute India’s first dengue vaccine QDENGA” »

]]>

While Dr. Reddy’s will exclusively manage private-market distribution, disease awareness, and healthcare professional engagement, Takeda will retain rights for the public market, legal ownership, and overall medical and brand oversight. File
| Photo Credit: Reuters

Dr. Reddy’s Laboratories on Friday (September 18, 2026) entered into an exclusive distribution agreement with Takeda Pharmaceutical Company to promote and distribute its dengue vaccine, QDENGA, in India’s private market for pediatric and adult vaccination.

Subject to local regulatory processes, the vaccine is expected to be available in the first half of 2027. The vaccine received marketing authorisation by the Central Drugs Standard Control Organization (CDSCO) in July 2026 for individuals aged 4-60 years, Dr. Reddy’s said in a press release.

QDENGA, a live-attenuated tetravalent vaccine, aims to strengthen dengue prevention and management by providing broad immune coverage across all four circulating dengue virus serotypes (DENV-1 to DENV-4). Administered as a two-dose regimen given three months apart, it is India’s first approved dengue vaccine, according to the release.

While Dr. Reddy’s will exclusively manage private-market distribution, disease awareness, and healthcare professional engagement, Takeda will retain rights for the public market, legal ownership, and overall medical and brand oversight, it said.

“As the second-largest vaccine player in India, we believe the introduction of India’s first approved dengue vaccine is an important development for the country’s healthcare landscape,” said M. V. Ramana, CEO, Global Generics, Dr. Reddy’s Laboratories.

“Through our collaboration with Takeda, we look forward to making QDENGA available to eligible individuals and contributing to efforts aimed at addressing the country’s dengue burden,” Mr. Ramana said.

Dr. Mahender Nayak, Head of Intercontinental Markets, International Business Unit, Takeda, noted, “In parallel, our private-market collaboration with Dr. Reddy’s will help enable timely private-market access for eligible individuals once QDENGA becomes available in India.” Approved in 43 countries, QDENGA has seen over 32 million doses distributed globally.



Source link

]]>
Dr. Reddy’s forays into India’s biosimilar immuno-oncology market, launches Nivorz https://artifex.news/article71469381-ece/ Tue, 15 Sep 2026 16:03:00 +0000 https://artifex.news/article71469381-ece/ Read More “Dr. Reddy’s forays into India’s biosimilar immuno-oncology market, launches Nivorz” »

]]>

Dr. Reddy’s Laboratories on Tuesday said it is foraying into the biosimilar immuno-oncology therapy segment in India with the launch of Nivorz, a biosimilar of Bristol Myers Squibb’s Opdivo (nivolumab).

The biosimilar has been developed and manufactured entirely in-house at its biologics facility in Bachupally, Hyderabad. The launch reflects the company’s end-to-end capabilities across the biosimilar value chain, from development through commercialisation, Dr. Reddy’s said.

In 2025, the immuno-oncology market in India was estimated to be around ₹3,900 crore and predominantly driven by checkpoint inhibitors such as nivolumab, pembrolizumab and toripalimab, it said.

“The launch of Nivorz strengthens our oncology portfolio and expands presence in immuno-oncology. As access to immunotherapy continues to be a challenge for many patients, we remain committed to improving access to high-quality treatment options through affordable biosimilars,” CEO Global Generics M.V. Ramana said.

The company said Nivorz was evaluated through a multi-country clinical development programme involving 288 patients, including 252 from India and 36 from Russia, and demonstrated comparable efficacy, safety, pharmacokinetics and immunogenicity to the reference nivolumab. Based on this clinical development programme, it has been approved in India by the Drugs Controller General of India (DCGI).

Global Head of Biologics at Dr. Reddy’s Sridevi Khambhampaty said “the launch of Nivorz marks an important milestone for the company’s biologics business. It reinforces our commitment to expanding patient access to high-quality and reflects our continued focus on developing complex biosimilars.”

Nivorz is one of the immunotherapy agents with the broadest range of approved indications in oncology in India. The approved indications span early-stage, locally advanced, recurrent and metastatic disease settings across both solid and hematological malignancies, the company said.



Source link

]]>
Dr. Reddy’s CDMO arm Aurigene inks long-term manufacturing pact with global pharma major https://artifex.news/article71389121-ece/ Tue, 25 Aug 2026 13:37:00 +0000 https://artifex.news/article71389121-ece/ Read More “Dr. Reddy’s CDMO arm Aurigene inks long-term manufacturing pact with global pharma major” »

]]>

Dr. Reddy’s Labs
| Photo Credit: The Hindu

Contract research, development and manufacturing organisation Aurigene Pharmaceutical Services, a subsidiary of Dr. Reddy’s Laboratories, has entered into a long-term manufacturing and supply agreement (MSA) with a leading global pharmaceutical company.

Under the agreement, Aurigene will undertake commercial drug-product manufacturing and supply for a diversified portfolio targeting markets across the U.S., Europe, Canada and emerging markets. The identity of the global pharmaceutical company has not been disclosed due to confidentiality obligations.

The initial portfolio comprises more than 20 products across sterile injectables, biologics and topical formulations, which will be manufactured at Aurigene’s facilities in India.

The partnership is expected to progress through a phased technology-transfer programme over the next two to three years, leading to commercial manufacturing and long-term supply. At full commercialisation, the portfolio is expected to generate annual volumes of around 18 million units, with injectables accounting for the bulk of the volumes. Revenue contribution from the agreement is expected to begin in calendar year 2028.

As part of the agreement, an end-to-end framework covering technical transfer, process development, scale-up, validation, commercial manufacturing and long-term supply would be established.

Aurigene Pharmaceutical Services CEO Akhil Ravi said the strategic collaboration reflects the confidence global innovators place in the company’s integrated drug-product development and manufacturing capabilities.

The partnership would provide long-term revenue visibility, accelerate the scale-up of Aurigene’s drug-product business and strengthen its focus on reliable, high-quality supply to patients worldwide, he added.



Source link

]]>
Dr. Reddy’s, Novartis India terminate agreement https://artifex.news/article71329348-ece/ Mon, 10 Aug 2026 15:50:00 +0000 https://artifex.news/article71329348-ece/ Read More “Dr. Reddy’s, Novartis India terminate agreement” »

]]>

Dr. Reddy’s Laboratories has ended its more than four-year relationship with Novartis India, terminating an agreement under which it distributed and promoted select brands of the Swiss drugmaker in India.

The termination of the February 11, 2022, agreement follows a change in the controlling shareholding of Novartis India. It will continue to commercialise the brands covered under the agreement until September 30, 2026, Dr. Reddy’s said in a filing recently.

Separately, Novartis India said the termination agreement was executed on August 7. Consequently, it will re-acquire exclusivity and secure market access for the products for which Dr. Reddy’s was granted exclusive and non-transferable right to promote, distribute and sell.

Novartis India, previously a part of Swiss multinational Novartis AG, announced on July 29 private equity firm ChrysCapital acquiring a controlling 70.68% stake. Pain management, calcium supplementation, gynaecology, neurosciences and transplant immunology through brands such as Voveran, Calcium Sandoz and Tegrital are among the key therapeutic areas in which Novartis India operates.

For ChrysCapital, the acquisition marks first majority-controlled investment in the Indian pharmaceutical sector. It reflects the firm’s strong conviction in the long-term growth potential of India’s branded pharmaceuticals market, Novartis India said.



Source link

]]>
Dr. Reddy’s Srikakulam facility gets 3 U.S. FDA observations https://artifex.news/article71286036-ece/ Thu, 30 Jul 2026 13:47:00 +0000 https://artifex.news/article71286036-ece/ Read More “Dr. Reddy’s Srikakulam facility gets 3 U.S. FDA observations” »

]]>

A view of Dr. Reddy’s Lab facility near Hyderabad.
| Photo Credit: The Hindu

Dr. Reddy’s Laboratories has been issued three observations by the U.S. Food and Drug Administration (U.S. FDA) after an inspection of its facility in Srikakulam, Andhra Pradesh.

The U.S. FDA has completed a Pre-Approval Inspection (PAI) and Good Manufacturing Practices (GMP) inspection at the FTO-SEZ Process Unit-02 in Srikakulam. The inspection was conducted between July 20 and July 29, the Hyderabad-based generic drugmaker said in a filing on Wednesday (July 29, 2026).

“We have been issued a Form 483 with three observations, which we will address within the stipulated timeline,” Dr. Reddy’s said. The company’s shares closed flat on Thursday (July 30, 2026) at ₹1,144.35 a piece on the Bombay Stock Exchange.



Source link

]]>
Dr. Reddy’s Q1 net plunges 69% to ₹435.6 cr on lower revenue https://artifex.news/article71253745-ece/ Wed, 22 Jul 2026 14:16:00 +0000 https://artifex.news/article71253745-ece/ Read More “Dr. Reddy’s Q1 net plunges 69% to ₹435.6 cr on lower revenue” »

]]>

Hyderabad-based generic drugmaker Dr. Reddy’s Laboratories’ consolidated net profit slumped 69% year-on-year (YoY) to ₹.435.6 crore in the June quarter amid lower sales of cancer drug lenalidomide and nearly ₹240 crore provision necessitated by recent quality issue around weight loss drug Semaglutide.

Total revenue from operations stood at ₹8,099.8 crore (₹8,572.1 crore), showed its results prepared in accordance with Indian Accounting Standards (Ind AS).

“Our Q1FY27 performance reflected the expected transition beyond lenalidomide revenues, along with an unexpected impact related to semaglutide active pharmaceutical ingredient (API). However, our underlying base business continued to deliver healthy double digit growth across all key geographies,” co-chairman and managing director G V Prasad said.

The focus remains on improving health of the base business through disciplined execution and operational excellence, while building future pipeline of peptides, biosimilars and innovative assets to deliver long-term growth, he said.

An adverse product mix, primarily on account of reduced sales of lenalidomide (generic of Revlimid), price erosion in North America and Europe generics, the semaglutide API related provision impact besides elevated solvent costs and freight costs on account of the Middle East crisis impacted the gross margin, Dr. Reddy’s said.

The underlying base business, excluding lenalidomide, continued to deliver healthy double-digit growth across all geographies, including North America, aided by favourable currency movements.

On the provision, the drugmaker said certain batches of Semaglutide were found to be out of specification due to an issue associated with the API used in the product. “Consequently, based on its best estimate, the company has made a provision of ₹.239.7 crore towards inventory and other associated costs during the quarter ended June 30, 2026,” it said.



Source link

]]>